Study: NCT02582775

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow infusion
Description: Bone marrow infusion on Day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow infusion
Description: Bone marrow infusion on Day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow infusion
Description: Bone marrow infusion on Day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow infusion
Description: Bone marrow infusion on Day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow infusion
Description: Bone marrow infusion on Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors). When used in non-MSD recipients, tapered over 6-8 weeks starting at day +100.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors). When used in non-MSD recipients, tapered over 6-8 weeks starting at day +100.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors). When used in non-MSD recipients, tapered over 6-8 weeks starting at day +100.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors). When used in non-MSD recipients, tapered over 6-8 weeks starting at day +100.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors). When used in non-MSD recipients, tapered over 6-8 weeks starting at day +100.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors). When used in non-MSD recipients, tapered over 6-8 weeks starting at day +100.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors). When used in non-MSD recipients, tapered over 6-8 weeks starting at day +100.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors). When used in non-MSD recipients, tapered over 6-8 weeks starting at day +100.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor mesenchymal stem cell infusions
Description: Day 60, 100 and 180 (collected during donor BM harvest for graft)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor mesenchymal stem cell infusions
Description: Day 60, 100 and 180 (collected during donor BM harvest for graft)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor mesenchymal stem cell infusions
Description: Day 60, 100 and 180 (collected during donor BM harvest for graft)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor mesenchymal stem cell infusions
Description: Day 60, 100 and 180 (collected during donor BM harvest for graft)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor mesenchymal stem cell infusions
Description: Day 60, 100 and 180 (collected during donor BM harvest for graft)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor mesenchymal stem cell infusions
Description: Day 60, 100 and 180 (collected during donor BM harvest for graft)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor mesenchymal stem cell infusions
Description: Day 60, 100 and 180 (collected during donor BM harvest for graft)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor mesenchymal stem cell infusions
Description: Day 60, 100 and 180 (collected during donor BM harvest for graft)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: busulfan IV over 3 hours on days -3 and -2 for HLA-mismatched BM recipients only (Arms F and G)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: busulfan IV over 3 hours on days -3 and -2 for HLA-mismatched BM recipients only (Arms F and G)